Publicaciones en colaboración con investigadores/as de Monash University (15)

2023

  1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248

  2. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

    Leukemia

  3. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  4. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria

    Seminars in Hematology

  5. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology

  6. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

  7. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

    Seminars in Hematology

  8. SARS-CoV-2 Infection in Patients with Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study

    HemaSphere

  9. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106

2022

  1. IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385

  2. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

    Blood Advances

2021

  1. Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients

    International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336

2020

  1. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

    Blood, Vol. 136, Núm. 18, pp. 2038-2050

  2. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial

    Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018

2013

  1. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease

    Journal of Clinical Oncology, Vol. 31, Núm. 18, pp. 2347-2357